Poly Medicure Ltd (POLYMED) — shareholding pattern, promoter holding, financials and share price
About Poly Medicure Ltd (POLYMED)
Poly Medicure Ltd operates in the Medical Equipment & Supplies industry, within the Healthcare sector. It trades on the NSE as POLYMED and on the BSE under scrip code 531768. Its ISIN is INE205C01021.
Poly Medicure Limited is an India-based manufacturer and exporter of medical devices. The Company exports plastic medical disposables/surgical devices. [1]
Poly Medicure Limited is an India-headquartered medical devices manufacturer supplying infusion therapy, renal/dialysis, cardiology, orthopedics and other fluid-management products to over 125 countries, operating multiple manufacturing sites across India, China, Egypt and Italy and selling through a global distributor network and recently acquired European businesses.
Q3 FY26 consolidated revenue rose 16.4% YoY to Rs.493.7 crore with gross margin expansion (~300 bps YoY) but reported PAT compression due to one-off labour-code provisioning and acquisition-related expenses; consolidated operating EBITDA margin remains within the 25–27% guidance band at 24.2% for the quarter and 25.8% for 9M.
Listed peers in Medical Equipment & Supplies: Fischer Medical Ventures Ltd, Tarsons Products Ltd, Q-Line Biotech Ltd, Laxmi Dental Ltd, OSEL Devices Ltd, Fabtech Technologies Ltd.
Valuation & Returns
10 Jul 2026At ₹1,670 a share on 10 Jul 2026, Poly Medicure Ltd (POLYMED) was valued at a price-to-earnings ratio of 52.78x against an industry P/E of 44.11x and a price-to-book of 6.12x on a book value of ₹272.86 per share as of Mar 2025. Solomo computes return on equity of 11.6% and return on capital employed of 15.13% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 52.78x
- Industry P/E
- 44.11x
- P/B
- 6.12x
- EPS (TTM)
- ₹31.64
- Book value / share
- ₹272.86
- ROE
- 11.6%
- ROCE
- 15.13%
- ROA
- 10.05%
- Debt / equity
- 0.07x
- Dividend yield
- 0.21%
- EBITDA margin
- 29.91%
- 52-week range
- ₹1,184 – ₹2,238.4
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Poly Medicure Ltd (POLYMED) reported revenue of ₹1,875 crore, net profit of ₹321 crore and earnings per share of ₹31.78. That compares with revenue of ₹1,669 crore and net profit of ₹339 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹535 crore and net profit ₹65 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 922 | 1,115 | 1,375 | 1,669 | 1,875 |
| Net profit (₹ cr) | 147 | 179 | 258 | 339 | 321 |
| EPS (₹) | 15.28 | 18.69 | 26.91 | 33.41 | 31.78 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 16.66% | 19.91% | 22.13% | 21.37% |
| Profit growth | 24.14% | 29.10% | 31.41% | 31.09% |
| Stock price CAGR | 23% | 12% | 17% | -18% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 62.42% of Poly Medicure Ltd (POLYMED) (unchanged from the previous quarter), foreign institutional investors (FII) hold 5.57% and domestic institutional investors (DII) hold 16.08%. Market capitalisation was ₹16,927 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: QUANT MUTUAL FUND - QSIF HYBRID LONG-SHORT FUND 4.61%, LIGHTHOUSE INDIA FUND IV AIF 2.33%, AXIS MAX LIFE INSURANCE LIMITED A/C UEGFH - HIGH GROWTH FUND II 2.14%, UTI-UNIT LINKED INSURANCE PLAN 1.52%, SBI NIFTY SMALLCAP 250 ETF 1.22%, NIRMALA VINODKUMAR DAGA 1.16%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 62.42% | - | 5.57% | 16.08% | 37.58% |
| Mar 2026 | 62.42% | - | 5.91% | 15.59% | 37.58% |
| Dec 2025 | 62.42% | - | 9.4% | 13.84% | 37.58% |
| Sep 2025 | 62.42% | - | 9.77% | 13.54% | 37.58% |
| Jun 2025 | 62.44% | - | 11.41% | 11.72% | 37.56% |
| Mar 2025 | 62.44% | - | 11.46% | 11.96% | 37.56% |
| Dec 2024 | 62.44% | - | 12.33% | 11.66% | 37.56% |
| Sep 2024 | 62.56% | - | 11.87% | 12.33% | 37.44% |